Literature DB >> 35176166

How Can We Pursue Equity in Cervical Cancer Prevention With Existing HPV Genotype Differences?

Sarah P Huepenbecker1, Larissa A Meyer1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35176166      PMCID： PMC9194615          DOI： 10.1093/jnci/djac035

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  36 in total

1.  FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.

Authors:  Kayla Saadeh; Ina Park; Julia W Gargano; Erin Whitney; Troy D Querec; Leo Hurley; Michael Silverberg
Journal:  Vaccine       Date:  2019-10-11       Impact factor: 3.641

3.  Medicaid Expansions and Cervical Cancer Screening for Low-Income Women.

Authors:  Lindsay M Sabik; Wafa W Tarazi; Stephanie Hochhalter; Bassam Dahman; Cathy J Bradley
Journal:  Health Serv Res       Date:  2017-06-30       Impact factor: 3.402

4.  Cervical cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Vicki B Benard; Meg Watson; Mona Saraiya; Rhea Harewood; Julie S Townsend; Antoinette M Stroup; Hannah K Weir; Claudia Allemani
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

5.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Authors:  Hormuzd A Katki; Walter K Kinney; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Li Cheung; Franklin Demuth; Mark Schiffman; Sholom Wacholder; Philip E Castle
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

6.  Given a choice between self-sampling at home for HPV testing and standard of care screening at the clinic, what do African American women choose? Findings from a group randomized controlled trial.

Authors:  Isabel C Scarinci; Yufeng Li; Laura Tucker; Nicole G Campos; Jane J Kim; Sylvia Peral; Philip E Castle
Journal:  Prev Med       Date:  2020-12-16       Impact factor: 4.018

7.  State Medicaid expansion decisions and disparities in women's cancer screening.

Authors:  Lindsay M Sabik; Wafa W Tarazi; Cathy J Bradley
Journal:  Am J Prev Med       Date:  2014-10-30       Impact factor: 5.043

8.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

9.  Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management.

Authors:  Jacqueline Mix; Mona Saraiya; Benjamin D Hallowell; Brian Befano; Li C Cheung; Elizabeth R Unger; Julia W Gargano; Lauri E Markowitz; Philip E Castle; Tina Raine-Bennett; Joan Walker; Rosemary Zuna; Mark Schiffman; Nicolas Wentzensen; Julia C Gage
Journal:  J Natl Cancer Inst       Date:  2022-06-13       Impact factor: 11.816

10.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Authors:  Warner K Huh; Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Rosires Pereira de Andrade; Kevin A Ault; Deborah Bartholomew; Ramon M Cestero; Edison N Fedrizzi; Angelica L Hirschberg; Marie-Hélène Mayrand; Angela Maria Ruiz-Sternberg; Jack T Stapleton; Dorothy J Wiley; Alex Ferenczy; Robert Kurman; Brigitte M Ronnett; Mark H Stoler; Jack Cuzick; Suzanne M Garland; Susanne K Kjaer; Oliver M Bautista; Richard Haupt; Erin Moeller; Michael Ritter; Christine C Roberts; Christine Shields; Alain Luxembourg
Journal:  Lancet       Date:  2017-09-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.